TCT 2019 | COMPLETE: Sub-Study to Find Out Complete Optimal Revascularization Timing in STEMI

Courtesy of SBHCI.

The COMPLETE study was carried out to assess the benefit of complete revascularization vs culprit vessel revascularization in the context of ST elevation acute myocardial infarction. This COMPLETE sub-study presented at TCT 2019 scientific sessions simultaneously published in JACC assessed the optimal timing of complete revascularization. The general study had already shown the latter is superior to treating only the culprit vessel. 

Highlights TCT 2019

The sub-study assessed two groups: complete revascularization done during index hospitalization (n=2702) and complete revascularization after discharge (n=1339). Patients in the first group passed through the cath lab again at mean 1 day after infarction and patients in the second group at mean 23 days. 

Outcomes at 3 years for primary end point (composite of death and repeat MI) and secondary end points such as death, MI or ischemia driven revascularization were analyzed in both groups. 

For both the primary and secondary end points, both groups undergoing complete revascularization (during index hospitalization and after discharge) saw a benefit vs. culprit vessel revascularization alone. 

There seems to be no difference between complete revascularization at hospitalization or after discharge and in both arms the major benefit was observed after 45 days of MI. With this data we could speculate that complete revascularization should follow physician criterion on a case by case basis. Given the curves start growing apart more significantly as of day 45, it seems reasonable to do it before this point. 

Courtesy of SBHCI.

Link to the SBHCI publication HERE

complete-substudy

Original Title: COMPLETE TIMING SUBSTUDY – A Randomized Trial Of Complete Staged Revascularization Vs. Infarct Artery PCI Alone In Patients With Acute Myocardial Infarction And Multivessel Disease — Importance Of Revascularization Timing.

Author of the Original Article: David A. Wood.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

Drugs for the Treatment of No-Reflow During PCI

The no-reflow phenomenon is one of the most frustrating complications of primary angioplasty (pPCI), reflecting persistent microvascular damage that, in the mid- to long-term,...

Rotational atherectomy and its technical secrets: use of floppy or ES guidewire

Rotational atherectomy (RA) remains a very useful tool in the management of severe coronary calcification. However, many of its technical aspects rely more on...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...